23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

It is important to evaluate the role of the IF2 within the bacterial translation regulatory mechanism as well as to pose the IF2 as a molecular target for repurposed non-steroidal anti-inflammatory drugs (NSAIDS). The aim of this project is to identify a novel and an effective therapeutic endogenous molecular target in Mycobacterium tuberculosis. In this study, I have identified, cloned, expressed and partially purified the novel putative endogenous therapeutic target for various non-steroidal anti-inflammatory drugs (NSAIDs) from H37Rv strain of Mycobacterium tuberculosis: putative…mehr

Produktbeschreibung
It is important to evaluate the role of the IF2 within the bacterial translation regulatory mechanism as well as to pose the IF2 as a molecular target for repurposed non-steroidal anti-inflammatory drugs (NSAIDS). The aim of this project is to identify a novel and an effective therapeutic endogenous molecular target in Mycobacterium tuberculosis. In this study, I have identified, cloned, expressed and partially purified the novel putative endogenous therapeutic target for various non-steroidal anti-inflammatory drugs (NSAIDs) from H37Rv strain of Mycobacterium tuberculosis: putative mycobacterial infB, Rv2839c encoded protein which is putative protein translation initiation factor 2 (IF2) in a few species of mycobacteria. I conclude it may lead us to the discovery of the new anti-tubercular role of some old inexpensive NSAIDs and/or their derivatives as effective drugs against IF2 of Mycobacterium tuberculosis.
Autorenporträt
In 2013, I graduated from the Birkbeck College, University of London in the UK with a two years degree in Clinical Microbiology. The most important for me was my participation in cloning, heterologous expression and purification of a couple of putative molecular drug targets from Mycobacterium tuberculosis, with which I got Merit mark.